Cancer Immunology, Immunotherapy

, Volume 30, Issue 6, pp 342–350 | Cite as

Tumor-infiltrating lymphocytes from nonrenal urological malignancies

  • Gabriel P. Haas
  • Diane Solomon
  • Steven A. Rosenberg
Original articles


Tumor-infiltrating lymphocytes (TIL) were isolated from 15 of 20 surgical specimens of transitional cell carcinoma of the urinary bladder, prostate cancer, testicular cancer, Wilms tumor and adrenal cancer. Expansion was carried out in four different culture conditions, each containing 1000 U/ml interleukin-2: RPMI medium with or without 20% (by volume) of lymphokine-activated killer cell (LAK) supernatant and AIM V medium with or without 20% LAK supernatant. The resultant cell populations were then assayed for cytotoxicity against a variety of autologous and allogeneic tumor targets and phenotypic analysis was performed with fluorescein-labeled monoclonal antibodies. TIL growth was unrelated to the initial percentage of lymphocytes or tumor cells present in the enzymatically dispersed specimens or whether fresh or cryopreserved tissue was utilized. Better growth was seen in AIM V than in RPMI medium (P = 0.013); the beneficial effect of the addition of LAK supernatant to RPMI was indicated (P = 0.065), and the addition of LAK supernatant to AIM V did not improve the ability to culture TIL (P = 0.5) from these cancers. TIL in long-term culture were predominantly CD3+. The ratio of CD4+/CD8+ cells varied with time in culture and culture medium, but most cultures eventually became CD4+. Cells bearing B cell, natural killer cell, and macrophage markers disappeared early in culture. Overall 14/15 TIL samples were lytic against one of the autologous and allogeneic targets tested, but specific lysis against the autologous tumor from which it was derived was seen in only one TIL culture originating from a bladder cancer. Our results suggest that TIL can be expanded to therapeutic levels from a variety of urological malignancies and that their potential role in future therapy should be further explored.


Natural Killer Cell Transitional Cell Carcinoma Testicular Cancer Autologous Tumor Macrophage Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Belldegrun A, Linehan WM, Robertson CN, Rosenberg SA (1986) Isolation and characterization of lymphocytes infiltrating human cancer: possible application for therapeutic adoptive immunotherapy. Surg Forum 37: 671Google Scholar
  2. 2.
    Belldegrun A, Muul L, Rosenberg SA (1988) Interleukin-2 expanded tumor infiltrating lymphocytes in human renal cell cancer: isolation, characterization and antitumor activity. Cancer Res 48: 206PubMedGoogle Scholar
  3. 3.
    Cozzolino F, Torcia M, Carossino AM, Giordani R, Selli C, Talini G, Reali E, Novelli A, Pistoia V, Ferrarini M (1987) Characterization of cells from invaded lymph nodes in patients with solid tumors: lymphokine requirement for tumorspecific lymphoproliferative response. J Exp Med 166: 303PubMedGoogle Scholar
  4. 4.
    Galili V, Vanky F, Rodriguez L, Klein E (1979) Activated T lymphocytes within human solid tumors. Cancer Immunol Immunotherapy 6: 129Google Scholar
  5. 5.
    Haskill S. Some historical prospectives on the relationship between survival and mononuclear cell infiltration. (1982) In: Tumor immunity and prognosis. The Role of Mononuclear Cell Infiltration, Marcel Dekker, New YorkGoogle Scholar
  6. 6.
    Heo DS, Whiteside TL, Johnson JT, Chen K, Barnes EL, Herberman RB (1987). Long-term interleukin-2 dependent growth and cytotoxic activity of tumor infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res 47: 6353PubMedGoogle Scholar
  7. 7.
    Heo DS, Whiteside TL, Kanbour A, Herberman RB (1988). I. Role of Leu-19 (NKH1) positive recombinant IL-2 activated cultures of lymphocytes infiltrating human ovarian tumors. J Immunol 140: 4042PubMedGoogle Scholar
  8. 8.
    Itoh K, Tilden AB, Balch CM (1986) Interleukin-2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 46: 3011PubMedGoogle Scholar
  9. 9.
    Kradin RL, Boyle LA, Preffer FI, Callahan RJ, Barlai-Kovach M, Strauss HW, Dubinett S, Kurnick JT (1987) Tumorderived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 24: 76PubMedGoogle Scholar
  10. 10.
    Miescher S, Whiteside TL, Moretta L, Von Fliedner V (1987) Clonal and frequency analysis of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 138: 4004PubMedGoogle Scholar
  11. 11.
    Muul LM, Spiess PJ, Director EP, Rosenberg SA (1987) Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138: 989PubMedGoogle Scholar
  12. 12.
    Muul LM, Nason-Burchenal K, Hyatt C, Schwarz S, Slavin D, Director EP, Rosenberg SA (1987) Studies of serum free culture medium in the generation of lymphokine activated killer cells. J Immunol Methods 105: 183PubMedGoogle Scholar
  13. 13.
    Poppema S, Brocker EB, De Leij L, Terbrack D, Visscher T, Terhaar A, Macher E, Sorg C (1983) In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol 51: 77PubMedGoogle Scholar
  14. 14.
    Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A (1987) Functional analysis of mononuclear cell infiltrating tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 47: 173PubMedGoogle Scholar
  15. 15.
    Rosenberg SA, Speiss P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233: 1318PubMedGoogle Scholar
  16. 16.
    Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei J, White D (1988) Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676PubMedGoogle Scholar
  17. 17.
    Singluff CL, Darrow TL, Seigler HF (1987) Human T cells specifically activated against autologous melanoma. Arch Surg 122: 1407PubMedGoogle Scholar
  18. 18.
    Topalian SL, Muul LM, Rosenberg SA (1987) Growth and immunologic characteristics of lymphocytes infiltrating human tumor. Surg Forum 37: 390Google Scholar
  19. 19.
    Topalian SL, Muul LM, Solomon D, Rosenberg SA (1987) Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102: 127PubMedGoogle Scholar
  20. 20.
    Topalian SL, Solomon DL, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA (1988) Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 6: 839PubMedGoogle Scholar
  21. 21.
    Tsujihasie H, Matsuda H, Uejima S, Akiyama T, Kurita T (1988) Immunocompetence of tissue infiltrating lymphocytes in bladder tumors. J Urol 140: 890PubMedGoogle Scholar
  22. 22.
    Whiteside TL, Miescher S, Hurliman J, Moretta L, von Fliedner V (1986) Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother 23: 169PubMedGoogle Scholar
  23. 23.
    Yron I, Wood TA, Spiess PJ, Rosenberg SA (1980) The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 125: 238PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Gabriel P. Haas
    • 1
  • Diane Solomon
    • 2
  • Steven A. Rosenberg
    • 1
  1. 1.Surgery BranchNational Institutes of HealthBethesdaUSA
  2. 2.Section of Cytopathology, Laboratory of Pathology, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations